Type I interferon is selectively required by dendritic cells for immune rejection of tumors.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsDiamond, Mark S
Dunn, Gavin P
Archambault, Jessica M
Arthur, Cora D
White, J Michael
Murphy, Kenneth M
Schreiber, Robert D
MetadataShow full item record
AbstractCancer immunoediting is the process whereby the immune system suppresses neoplastic growth and shapes tumor immunogenicity. We previously reported that type I interferon (IFN-α/β) plays a central role in this process and that hematopoietic cells represent critical targets of type I IFN's actions. However, the specific cells affected by IFN-α/β and the functional processes that type I IFN induces remain undefined. Herein, we show that type I IFN is required to initiate the antitumor response and that its actions are temporally distinct from IFN-γ during cancer immunoediting. Using mixed bone marrow chimeric mice, we demonstrate that type I IFN sensitivity selectively within the innate immune compartment is essential for tumor-specific T cell priming and tumor elimination. We further show that mice lacking IFNAR1 (IFN-α/β receptor 1) in dendritic cells (DCs; Itgax-Cre(+)Ifnar1(f/f) mice) cannot reject highly immunogenic tumor cells and that CD8α(+) DCs from these mice display defects in antigen cross-presentation to CD8(+) T cells. In contrast, mice depleted of NK cells or mice that lack IFNAR1 in granulocytes and macrophage populations reject these tumors normally. Thus, DCs and specifically CD8α(+) DCs are functionally relevant targets of endogenous type I IFN during lymphocyte-mediated tumor rejection.
CitationType I interferon is selectively required by dendritic cells for immune rejection of tumors. 2011, 208 (10):1989-2003 J. Exp. Med.
AffiliationDepartment of Pathology and Immunology, School of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
The following license files are associated with this item:
- Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.
- Authors: Wei J, Waithman J, Lata R, Mifsud NA, Cebon J, Kay T, Smyth MJ, Sadler AJ, Chen W
- Issue date: 2010 Nov 15
- Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
- Authors: Tanaka F, Hashimoto W, Okamura H, Robbins PD, Lotze MT, Tahara H
- Issue date: 2000 Sep 1
- Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant.
- Authors: Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, Salazar AM, Colonna M, Steinman RM
- Issue date: 2009 Jul 6
- Dendritic cell therapy with interferon-alpha synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model.
- Authors: Ishii S, Hiroishi K, Eguchi J, Hiraide A, Imawari M
- Issue date: 2006 Jan
- Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1.
- Authors: Crouse J, Bedenikovic G, Wiesel M, Ibberson M, Xenarios I, Von Laer D, Kalinke U, Vivier E, Jonjic S, Oxenius A
- Issue date: 2014 Jun 19